跳至主要内容
临床试验/RPCEC00000368
RPCEC00000368招募中未知

Evaluation of the immune response generated after vaccination with CIMAvax-EGF using different maintenance schedules.

Center of Molecular Immunology (CIM)0 个研究点目标入组 42 人开始时间: 2021年5月12日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment

入排标准

年龄范围
18 years 至 one(—)
性别
All

入选标准

  • 1. Patients with a cytological / histological diagnosis of non-small cell lung carcinoma in all stages IIIb and IV, of any sex and age equal to or greater than 18 years, who have completed at least 2 cycles of first-line chemotherapy.
  • 2. Patients who have signed the informed consent for the research.
  • 3. Patients with clinical status criteria (ECOG) from 0 to 2.

排除标准

  • 1. Patients of childbearing potential who are not using an adequate method of contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms) while the treatment lasts.
  • 2. Pregnant, lactating or postpartum patients.
  • 3. Patients with uncontrolled intercurrent illnesses including, but not limited to: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes mellitus, arterial hypertension and psychiatric illnesses that imply the incompetence of the subject.
  • 4. Patients with brain metastases.

研究者

发起方
Center of Molecular Immunology (CIM)

相似试验